{
    "clinical_study": {
        "@rank": "99369", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Evaluate immunomodulation with extracorporeal photochemotherapy (ECP) in\n      patients with epidermolysis bullosa acquisita.\n\n      II.  Investigate the effect of ECP on lymphocyte activity."
        }, 
        "brief_title": "Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita", 
        "condition": "Epidermolysis Bullosa Acquisita", 
        "condition_browse": {
            "mesh_term": [
                "Epidermolysis Bullosa", 
                "Epidermolysis Bullosa Acquisita"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: Oral methoxsalen (8-MOP) is administered 90 minutes prior to\n      leukapheresis. Blood mononuclear cells are exposed to ultraviolet A light for 3 hours, then\n      returned to the patient.  The process is repeated on 2 successive days.\n\n      Patients are re-treated every 3 to 4 weeks for a total of 6 treatments or until the skin has\n      cleared."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Active epidermolysis bullosa acquisita"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "10", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004359", 
            "org_study_id": "199/11928", 
            "secondary_id": "NU-511"
        }, 
        "intervention": {
            "intervention_name": "methoxsalen", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Methoxsalen"
        }, 
        "keyword": [
            "dermatologic disorders", 
            "epidermolysis bullosa", 
            "genetic diseases and dysmorphic syndromes", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Northwestern University", 
            "last_name": "Kenneth B. Gordon", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004359"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "Northwestern University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "February 1996", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2000"
    }, 
    "geocoordinates": {}
}